Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Low-Dose Aspirin Treatment for Preterm Preeclampsia
N Engl J Med; ePub 2017 Jun 28; Rolnik, et al
In women at high risk for preterm preeclampsia, treatment with low-dose aspirin resulted in a lower incidence of this diagnosis when compared with placebo, a recent study found. The double-blind, placebo-controlled trial assigned 1,776 women with singleton pregnancies who were at high risk for preterm preeclampsia to receive aspirin (150 mg/day) or placebo from 11 to 14 weeks of gestation until 36 weeks of gestation. Researchers found:
- There was a total of 798 women in the aspirin group and 822 in the placebo group after study withdrawals.
- 13 participants (1.6%) in the aspirin group had preterm preeclampsia occurrence compared with 35 (4.3%) in the placebo group (odds ratio in the aspirin group, 0.38).
- Adherence was strong in both groups.
- There were no significant between-group differences in the incidence of neonatal adverse outcomes or other adverse events.
Citation:
Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. [Published online ahead of print June 28, 2017]. N Engl J Med. doi:10.1056/NEJMoa1704559.